MX2011012267A - Metodos para proveer pruebas de medicina personalizadas ex vivo en cuanto a neoplasmas hematologicos. - Google Patents
Metodos para proveer pruebas de medicina personalizadas ex vivo en cuanto a neoplasmas hematologicos.Info
- Publication number
- MX2011012267A MX2011012267A MX2011012267A MX2011012267A MX2011012267A MX 2011012267 A MX2011012267 A MX 2011012267A MX 2011012267 A MX2011012267 A MX 2011012267A MX 2011012267 A MX2011012267 A MX 2011012267A MX 2011012267 A MX2011012267 A MX 2011012267A
- Authority
- MX
- Mexico
- Prior art keywords
- vivo
- methods
- personalized medicine
- providing personalized
- hematological neoplasms
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Se describen métodos, dispositivos y composiciones para proveer pruebas de medicina personalizadas en cuanto a neoplasmas hematológicos. En algunas modalidades, los métodos comprenden medir la eficacia de inducir apoptosis selectivamente en células malignas usando cualquier número de tratamientos de fármacos combinados alternativos potenciales. En algunas modalidades, las pruebas ex vivo son medidas usando muestras hematológicas de paciente extraídas recientemente. En otras modalidades, la eficacia es medida ex vivo usando una plataforma de citometría de flujo automatizada. Por ejemplo, al usar una plataforma de citometría de flujo automatizada, la evaluación de cientos o aún miles de fármacos y composiciones puede ser efectuada ex vivo. Así, se pueden explorar tratamientos de poli-terapia alternativos. Los fármacos no citotóxicos inducen apoptosis selectivamente en células malignas ex vivo. En algunas modalidades, los métodos descritos en la presente comprenden evaluar fármacos no citotóxicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17968509P | 2009-05-19 | 2009-05-19 | |
PCT/US2010/035474 WO2010135468A1 (en) | 2009-05-19 | 2010-05-19 | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011012267A true MX2011012267A (es) | 2012-04-11 |
Family
ID=42342776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011012267A MX2011012267A (es) | 2009-05-19 | 2010-05-19 | Metodos para proveer pruebas de medicina personalizadas ex vivo en cuanto a neoplasmas hematologicos. |
Country Status (17)
Country | Link |
---|---|
US (2) | US20100298255A1 (es) |
EP (1) | EP2433124B1 (es) |
JP (1) | JP5851984B2 (es) |
CN (1) | CN102460165B (es) |
AR (1) | AR076590A1 (es) |
AU (1) | AU2010249593B2 (es) |
BR (1) | BRPI1012980A2 (es) |
CA (1) | CA2762783C (es) |
CL (1) | CL2011002905A1 (es) |
DK (1) | DK2433124T3 (es) |
ES (1) | ES2628219T3 (es) |
IL (1) | IL216419A (es) |
MX (1) | MX2011012267A (es) |
RU (1) | RU2636614C2 (es) |
SG (2) | SG10201402346UA (es) |
TW (1) | TWI546537B (es) |
WO (1) | WO2010135468A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130226469A1 (en) * | 2008-04-01 | 2013-08-29 | Purdue Research Foundation | Gate-free flow cytometry data analysis |
US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
EP2646830B1 (en) | 2010-12-03 | 2016-04-13 | Cellply S.R.L. | Rapid screening of monoclonal antibodies |
TWI503545B (zh) * | 2010-12-24 | 2015-10-11 | Methods of Screening Probiotics for Individual Differences | |
KR101992502B1 (ko) * | 2011-05-12 | 2019-06-24 | 제넨테크, 인크. | 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법 |
JP6541350B2 (ja) | 2011-11-09 | 2019-07-10 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗cxcr4抗体による血液悪性腫瘍の処置 |
KR101327533B1 (ko) * | 2012-12-11 | 2013-11-08 | 사회복지법인 삼성생명공익재단 | 환자 맞춤형 항암제 선별용 시스템 |
CA2919652A1 (en) | 2013-07-29 | 2015-02-05 | The Regents Of The University Of California | Real-time feedback system control technology platform with dynamically changing stimulations |
EP2959904A1 (en) * | 2014-06-27 | 2015-12-30 | Institut De Recerca Contra La Leucemia Josep Carreras | Methods for treating, diagnosing and prognosing a haematological malignancy |
CN104606207A (zh) * | 2015-02-09 | 2015-05-13 | 南京格耀生物科技有限公司 | 磺胺甲恶唑在制备抑制肿瘤细胞转移和扩散的药物中的应用 |
CN104958312A (zh) * | 2015-05-14 | 2015-10-07 | 四川大学华西医院 | 一种治疗急性淋巴细胞白血病的联合用药物 |
JP6774685B2 (ja) * | 2015-11-04 | 2020-10-28 | ヴィヴィア バイオテック,エス.エル | 薬物又は薬物の組み合わせに対する初代細胞集団の細胞応答性を試験するためのエクスビボの方法 |
MY193531A (en) * | 2015-11-11 | 2022-10-18 | Celator Pharmaceuticals Inc | Assays and methods for selecting a treatment regimen for a subject with leukemia |
JP7038353B2 (ja) | 2016-04-13 | 2022-03-18 | ヴィヴィア バイオテック,エス.エル | エクスビボのbite活性化t細胞 |
CN106093394B (zh) * | 2016-06-07 | 2017-12-26 | 中国人民解放军第二军医大学 | Flt3蛋白在制备肝癌对索拉菲尼疗效评估试剂盒中的应用 |
CA3027317A1 (en) | 2016-06-14 | 2017-12-21 | Cellply S.R.L. | Screening kit and method |
CA3079310A1 (en) | 2017-10-18 | 2019-04-25 | Vivia Biotech, S.L. | Bite-activated car-t cells |
EP3704484A1 (en) | 2017-10-31 | 2020-09-09 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Methods for determining selectivity of test compounds |
US11116692B2 (en) | 2018-06-07 | 2021-09-14 | Gecko Alliance Group Inc. | Method, system, computer program product and device for facilitating centralized control and monitoring over a network of a set of remote bathing unit systems |
WO2020043716A1 (en) * | 2018-08-27 | 2020-03-05 | Katholieke Universiteit Leuven | Pharmacological targeting of de novo serine/glycine synthesis |
WO2020074723A1 (en) * | 2018-10-11 | 2020-04-16 | Vivia Biotech Sl | A method for determining the efficacy of treatment with a combination of drugs in a subject diagnosed with a disease and a method for classifying the utility of drug combinations in treatment of said subject |
WO2020102595A1 (en) * | 2018-11-14 | 2020-05-22 | Dana-Farber Cancer Institute, Inc. | Determining treatment response in single cells |
EP3887395A4 (en) * | 2018-11-30 | 2022-07-27 | Intima Bioscience, Inc. | METHODS FOR IDENTIFICATION OF IMMUNOMODULATORY GENES |
CN112569342A (zh) * | 2020-12-21 | 2021-03-30 | 中南大学 | 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物 |
CN115531391B (zh) * | 2022-11-03 | 2023-07-18 | 浙江大学 | 一种治疗白血病的药物及应用 |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2947289A (en) * | 1988-01-04 | 1989-08-01 | Oncotech Incorporated | Methods and apparatus assessing tumor resistance |
US5366885A (en) * | 1992-06-09 | 1994-11-22 | Barranco Iii Sam C | Method and kit for testing tumors for drug sensitivity |
US5474909A (en) * | 1992-08-07 | 1995-12-12 | Anticancer, Inc. | Noncolorimetric histoculture method for predicting drug response of tumors |
WO1996022085A1 (en) * | 1995-01-17 | 1996-07-25 | Pfizer Inc. | The use of sertraline to treat cancer patients |
US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
US5736129A (en) * | 1995-11-17 | 1998-04-07 | Medenica; Rajko D. | Flow cytometric pharmacosensitivity assay and method of cancer treatment |
US6576636B2 (en) * | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
CN1219872A (zh) * | 1996-05-24 | 1999-06-16 | 血管技术药物公司 | 治疗或预防身体通道疾病的组合物和方法 |
US8828432B2 (en) * | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
US20030049618A1 (en) * | 1997-03-07 | 2003-03-13 | Ruben Steven M. | 186 human secreted proteins |
US7026447B2 (en) * | 1997-10-09 | 2006-04-11 | Human Genome Sciences, Inc. | 53 human secreted proteins |
US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US6207717B1 (en) * | 1999-01-12 | 2001-03-27 | Dow Corning Corporation | Entrapment of vitamins with an elastomeric silicone polyether |
US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
US6911306B1 (en) * | 1999-10-18 | 2005-06-28 | Emory University | TMS1 compositions and methods of use |
JP2003512856A (ja) * | 1999-11-04 | 2003-04-08 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | ウテログロビン様ポリヌクレオチド、ポリペプチド、および抗体 |
US6448030B1 (en) * | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
AU2002239771A1 (en) * | 2000-11-13 | 2002-06-18 | Vanderbilt University | Methods of predicting chemotherapy response |
IL139975A0 (en) * | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
US20050013853A1 (en) * | 2000-11-29 | 2005-01-20 | Irit Gil-Ad | Anti-proliferative drugs |
DE10064997A1 (de) * | 2000-12-23 | 2002-06-27 | Merck Patent Gmbh | Benzoylpyridazine |
MXPA03006885A (es) * | 2001-01-31 | 2003-11-13 | Pfizer Prod Inc | Derivados de eteres utiles como agentes inhibidores de las isozimas pde4. |
EP1364949A4 (en) * | 2001-02-02 | 2005-11-23 | Takeda Pharmaceutical | INHIBITOR OF JNK |
ATE412893T1 (de) * | 2001-02-14 | 2008-11-15 | Evotec Ag | Dispensionsvorrichtung |
WO2002076404A2 (en) * | 2001-03-23 | 2002-10-03 | Protarga, Inc. | Fatty alcohol drug conjugates |
US20070021360A1 (en) * | 2001-04-24 | 2007-01-25 | Nyce Jonathan W | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase |
US20040072824A1 (en) * | 2001-06-01 | 2004-04-15 | Adam Telerman | Methods and compositions for the treatment of cancer |
US7355042B2 (en) * | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
EP1469877A4 (en) * | 2001-11-02 | 2008-08-20 | Tanox Inc | B-cell lymphoma-specific antigen for use in the diagnosis and treatment of malignant B cell lesions |
US20040072181A1 (en) * | 2002-01-22 | 2004-04-15 | Whitehead Alexander Steven | Methods for determining drug responsiveness |
GB0202337D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Birmingham | Cancer treatment |
GB0203276D0 (en) * | 2002-02-12 | 2002-03-27 | Novartis Ag | Organic compounds |
DE10214388A1 (de) * | 2002-03-30 | 2003-10-16 | Cognis Deutschland Gmbh | Verfahren zur Herstellung fester Mittel |
WO2003102158A2 (en) * | 2002-05-31 | 2003-12-11 | The Forsyth Institute | Methods for increasing bone density |
EP1578434A2 (en) * | 2002-07-09 | 2005-09-28 | Point Therapeutics, Inc. | Methods and compositions relating to isoleucine boroproline compounds |
CN1389462A (zh) * | 2002-07-12 | 2003-01-08 | 复旦大学 | 大叶蒟素及其同系物,和在制备药物组合物中的应用 |
US20060009378A1 (en) * | 2002-11-14 | 2006-01-12 | Itshak Golan | Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases |
US20040101477A1 (en) * | 2002-11-27 | 2004-05-27 | Xanthus Life Sciences, Inc. | Individualization of therapy with anesthetics |
US20050013854A1 (en) * | 2003-04-09 | 2005-01-20 | Mannino Raphael J. | Novel encochleation methods, cochleates and methods of use |
WO2004091572A2 (en) * | 2003-04-09 | 2004-10-28 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
US7329638B2 (en) * | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
US20050136043A1 (en) * | 2003-08-07 | 2005-06-23 | Ludwig Institute For Cancer Research | TGFbeta signaling inhibitors |
SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
US9149440B2 (en) * | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
US20060127404A1 (en) * | 2003-09-30 | 2006-06-15 | Chichi Huang | Hinge core mimetibodies, compositions, methods and uses |
US20050143378A1 (en) * | 2003-12-29 | 2005-06-30 | Yun Anthony J. | Treatment of conditions through pharmacological modulation of the autonomic nervous system |
US9173847B2 (en) * | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
JP2007511528A (ja) * | 2003-11-13 | 2007-05-10 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 心肥大および心不全の処置としてのtrpチャネル阻害方法 |
US7211275B2 (en) * | 2004-01-16 | 2007-05-01 | Massachusetts Institute Of Technology | Composite materials for controlled release of water soluble products |
AU2005215134B2 (en) * | 2004-02-19 | 2009-01-29 | Novartis Ag | Use of cholinesterase inhibitors for treating vascular depression |
KR101462825B1 (ko) * | 2004-05-03 | 2014-11-21 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
WO2006088491A2 (en) * | 2004-06-29 | 2006-08-24 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
US20060009506A1 (en) * | 2004-07-09 | 2006-01-12 | Odyssey Thera, Inc. | Drugs for the treatment of neoplastic disorders |
DE502005008916D1 (de) * | 2004-07-23 | 2010-03-11 | Medicines Co Leipzig Gmbh | Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung |
US7566548B2 (en) * | 2004-08-13 | 2009-07-28 | University Of Massachusetts | Methods for identifying therapeutic agents and for treating disease |
US20060039975A1 (en) * | 2004-08-20 | 2006-02-23 | Zalman Vilkov | Paroxetine formulations |
EP1627610A1 (en) * | 2004-08-21 | 2006-02-22 | TLT Medical Ltd | Drug delivery throug application in nails |
US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
EP1792519A4 (en) * | 2004-09-10 | 2010-09-15 | Otologics Llc | ADJUSTABLE BONE CLAMP |
US20060058966A1 (en) * | 2004-09-15 | 2006-03-16 | Bruckner Howard W | Methods and systems for guiding selection of chemotherapeutic agents |
US20060062734A1 (en) * | 2004-09-20 | 2006-03-23 | Melker Richard J | Methods and systems for preventing diversion of prescription drugs |
CA2580694A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
WO2006035417A2 (en) * | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Dihydropyrimidine microcapsule - formulations |
CN101044249B (zh) * | 2004-10-20 | 2012-09-05 | 日立化成工业株式会社 | 通过定量mRNA定制给药的方法 |
JP2008518905A (ja) * | 2004-11-02 | 2008-06-05 | ファイザー株式会社 | スルホニルベンゾイミダゾール誘導体 |
EP1814390A4 (en) * | 2004-11-12 | 2009-07-01 | Univ Northwestern | METHOD FOR THE TREATMENT OF MOLECULAR BLOOD DISEASES WITH NUCLEOSIDE ANALOGUE |
WO2006069293A2 (en) * | 2004-12-22 | 2006-06-29 | Friedman Robert S | Composition comprising n-acetylcysteine and further pain or anti- inflamm medications |
CA2594505A1 (en) * | 2005-02-01 | 2006-08-10 | Icagen, Inc. | Imines as ion channel modulators |
CN101201349B (zh) * | 2005-03-17 | 2011-10-12 | 希森美康株式会社 | 试料分析装置和试料分析方法以及血液分析装置 |
US7601355B2 (en) * | 2005-06-01 | 2009-10-13 | Northwestern University | Compositions and methods for altering immune function |
US7655421B2 (en) * | 2005-06-17 | 2010-02-02 | Ciencia, Inc. | Cytometer on a chip |
JP2009501006A (ja) * | 2005-06-30 | 2009-01-15 | セントカー・インコーポレーテツド | 抗il−23抗体、組成物、方法および用途 |
WO2007011292A1 (en) * | 2005-07-21 | 2007-01-25 | Astrazeneca Ab | N-benzyl-morpholine derivatives as modulators of the chemokine receptor |
WO2007015926A2 (en) * | 2005-07-25 | 2007-02-08 | Oregon Health And Science University | Multiparameter flow cytometric cytometric cytotoxicity systems, methods, compositions and kits for evaluating the susceptibility of cancer |
AR058071A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de dihidropirazolo (3,4-e)(1,4)diazepina. procesos de obtencion y composiciones farmaceuticas. |
BRPI0520530A2 (pt) * | 2005-10-05 | 2009-09-29 | Astrazeneca Uk Ltd | método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb |
US20080318252A1 (en) * | 2007-04-23 | 2008-12-25 | Scott Kachlany | Rapid assay to test anti-cancer drugs under physiological conditions |
JP2009517453A (ja) * | 2005-12-02 | 2009-04-30 | ファイザー・リミテッド | Pde7阻害剤としてのスピロ環式キナゾリン誘導体 |
ES2334164T3 (es) * | 2005-12-15 | 2010-03-05 | Acusphere, Inc. | Procedimiento de preparacion de formulaciones farmaceuticas a base de particulas para administracion parenteral. |
JP2009528382A (ja) * | 2006-03-01 | 2009-08-06 | トリストラータ・インコーポレイテッド | タール応答性皮膚疾患の局所治療のための組成物及び方法 |
WO2007102059A1 (en) * | 2006-03-06 | 2007-09-13 | Pfizer Japan Inc. | Sulfonyl benzimidazole derivatives |
EP1996551A2 (en) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them. |
US20090029958A1 (en) * | 2006-03-08 | 2009-01-29 | Lilian Alcaraz | Phenethanolamine derivatives as beta2 adrenoreceptor agonists |
TW200808763A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
EP2032983A2 (en) * | 2006-05-24 | 2009-03-11 | Cellumen, Inc. | Method for modeling a disease |
TW200815469A (en) * | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
AU2007265239A1 (en) * | 2006-06-29 | 2008-01-03 | Janssen Pharmaceutica N.V. | Butyl and butynyl benzyl amine compounds |
AU2007284801A1 (en) * | 2006-08-08 | 2008-02-21 | The Regents Of The University Of Californina | Salicylanilides enhance oral delivery of therapeutic peptides |
US20080066739A1 (en) * | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
CN107445940A (zh) * | 2006-09-26 | 2017-12-08 | 细胞基因公司 | 作为抗肿瘤剂的5‑取代的喹唑酮衍生物 |
US8841300B2 (en) * | 2006-10-02 | 2014-09-23 | Jerry M. Held | Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor |
EP2078016B1 (en) * | 2006-10-19 | 2012-02-01 | Signal Pharmaceuticals LLC | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
US7661326B2 (en) * | 2006-10-26 | 2010-02-16 | Beckman Coulter, Inc. | Apparatus for aspirating and dispensing liquids in an automated analyzer |
TW200825084A (en) * | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
CN101677957A (zh) * | 2007-02-05 | 2010-03-24 | 卡比兰生物外科公司 | 用于递送生物活性试剂的聚合物制剂 |
GB0704000D0 (en) * | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | Salts 670 |
EP2129668A1 (en) * | 2007-03-07 | 2009-12-09 | Janssen Pharmaceutica N.V. | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
GB0707127D0 (en) * | 2007-04-13 | 2007-05-23 | Zysis Ltd | Pharmaceutical compositions |
US20090004281A1 (en) * | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
US7943658B2 (en) * | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
US9254268B2 (en) * | 2007-09-25 | 2016-02-09 | Solubest Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
US8354417B2 (en) * | 2007-09-26 | 2013-01-15 | Celgene Corporation | Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
JP5458359B2 (ja) * | 2007-10-18 | 2014-04-02 | 独立行政法人理化学研究所 | ヒト白血病幹細胞および白血病非幹細胞が増幅されたマウスおよびその製造方法 |
CA2703723A1 (en) * | 2007-10-19 | 2009-04-23 | Burnham Institute Of Medical Research | Inhibitors of anti-apoptotic proteins |
CA2703724C (en) * | 2007-10-19 | 2017-07-11 | Burnham Institute Of Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
US20110009496A1 (en) * | 2008-01-08 | 2011-01-13 | Sirtris Pharmaceuticas, Inc. | Resveratrol formulations |
RU2509077C2 (ru) * | 2008-05-27 | 2014-03-10 | Астразенека Аб | Феноксипиридиниламидные производные и их применение в лечении pde4-опосредованных болезненных состояний |
WO2010006291A1 (en) * | 2008-07-10 | 2010-01-14 | Nodality, Inc. | Methods for diagnosis, prognosis and treatment |
TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
WO2010045651A1 (en) * | 2008-10-17 | 2010-04-22 | Nodality, Inc. | Methods for analyzing drug response |
KR101046883B1 (ko) * | 2008-11-19 | 2011-07-06 | 재단법인 아산사회복지재단 | 항암제 치료약제에 대한 감수성을 일괄적으로 결정하는 방법 |
-
2010
- 2010-05-19 SG SG10201402346UA patent/SG10201402346UA/en unknown
- 2010-05-19 CN CN201080031427.8A patent/CN102460165B/zh active Active
- 2010-05-19 JP JP2012512006A patent/JP5851984B2/ja not_active Expired - Fee Related
- 2010-05-19 DK DK10721223.5T patent/DK2433124T3/en active
- 2010-05-19 WO PCT/US2010/035474 patent/WO2010135468A1/en active Application Filing
- 2010-05-19 MX MX2011012267A patent/MX2011012267A/es active IP Right Grant
- 2010-05-19 ES ES10721223.5T patent/ES2628219T3/es active Active
- 2010-05-19 AR ARP100101733A patent/AR076590A1/es active IP Right Grant
- 2010-05-19 US US12/783,465 patent/US20100298255A1/en not_active Abandoned
- 2010-05-19 CA CA2762783A patent/CA2762783C/en not_active Expired - Fee Related
- 2010-05-19 RU RU2011148289A patent/RU2636614C2/ru not_active IP Right Cessation
- 2010-05-19 SG SG2011085479A patent/SG176571A1/en unknown
- 2010-05-19 BR BRPI1012980A patent/BRPI1012980A2/pt not_active Application Discontinuation
- 2010-05-19 EP EP10721223.5A patent/EP2433124B1/en active Active
- 2010-05-19 AU AU2010249593A patent/AU2010249593B2/en not_active Ceased
- 2010-05-19 TW TW099115954A patent/TWI546537B/zh not_active IP Right Cessation
-
2011
- 2011-11-17 IL IL216419A patent/IL216419A/en not_active IP Right Cessation
- 2011-11-18 CL CL2011002905A patent/CL2011002905A1/es unknown
-
2017
- 2017-03-16 US US15/460,872 patent/US20170205395A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170205395A1 (en) | 2017-07-20 |
RU2636614C2 (ru) | 2017-11-24 |
JP2012527627A (ja) | 2012-11-08 |
IL216419A0 (en) | 2012-02-29 |
EP2433124A1 (en) | 2012-03-28 |
AR076590A1 (es) | 2011-06-22 |
CL2011002905A1 (es) | 2012-07-13 |
RU2011148289A (ru) | 2013-06-27 |
TW201043955A (en) | 2010-12-16 |
CA2762783C (en) | 2018-06-26 |
US20100298255A1 (en) | 2010-11-25 |
EP2433124B1 (en) | 2017-03-01 |
JP5851984B2 (ja) | 2016-02-03 |
AU2010249593A1 (en) | 2012-01-12 |
IL216419A (en) | 2016-05-31 |
CN102460165B (zh) | 2016-08-17 |
BRPI1012980A2 (pt) | 2016-03-29 |
WO2010135468A1 (en) | 2010-11-25 |
AU2010249593B2 (en) | 2016-03-17 |
CA2762783A1 (en) | 2010-11-25 |
SG176571A1 (en) | 2012-01-30 |
CN102460165A (zh) | 2012-05-16 |
SG10201402346UA (en) | 2014-10-30 |
DK2433124T3 (en) | 2017-06-19 |
ES2628219T3 (es) | 2017-08-02 |
TWI546537B (zh) | 2016-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011012267A (es) | Metodos para proveer pruebas de medicina personalizadas ex vivo en cuanto a neoplasmas hematologicos. | |
Chen et al. | Thymoquinone induces caspase-independent, autophagic cell death in CPT-11-resistant lovo colon cancer via mitochondrial dysfunction and activation of JNK and p38 | |
CO6680668A2 (es) | Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor | |
WO2011086174A3 (en) | Diagnostic gene expression platform | |
BR112013006207A2 (pt) | teste de diagnóstico molecular para câncer | |
TW200730129A (en) | Method and apparatus for point of care osmolarity testing | |
Ni et al. | Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing TLR4-triggered nuclear factor-kappa B activation | |
EP2416146A3 (en) | Probe for gas analysis | |
BRPI1007668A2 (pt) | aparelho de medição do batimento cardíaco, uso do aparelho de medição do batimento cardíaco, método, adaptado para medir o batimento cardíaco e/ou a variação do batimento cardíaco de um indivíduo | |
BR112013004534A2 (pt) | método para medir a tensão de cislhamento de um liquido de teste e aparelho de teste de fluido | |
EP2522743A3 (en) | Genetic variants contributing to risk of prostate cancer | |
BR112015000343A2 (pt) | tratador de sementes de baixo perfil com funcionalidade de medição | |
TN2015000161A1 (en) | Methylglyoxal as a marker of cancer | |
BR112013001417A2 (pt) | dispositivo para o teste de um indivíduo para a detecção de um estado de uma patologia vascular do indivíduo e método para o teste de um indivíduo para a detecção de um estado de uma patologia vascular do indivíduo | |
Davis | Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact. | |
EA201590686A1 (ru) | Тест на митохондриальную токсичность | |
Lin et al. | ATP-responsive mitochondrial probes for monitoring metabolic processes of glioma stem cells in a 3D model | |
WO2013182317A8 (en) | Probe card for an apparatus for testing electronic devices | |
GB2515713A (en) | Methods, packaging and apparatus for collection of biological samples | |
BR112021022896A2 (pt) | Método de seleção de regimes, ingredientes e composições de tratamento de pele | |
EP2044212A4 (en) | METHOD FOR IDENTIFYING PATIENTS WITH INCREASED RISK FOR AN UNWANTED HEART CIRCUIT EVENT | |
Chao et al. | The reliability and validity of the Chinese version of the Nonattachment Scale: Reliability, validity, and its relationship with mental health. | |
AU345335S (en) | Device for collecting and testing a fluid sample | |
ES2509567T3 (es) | Identificación de variación genética en tejidos afectados | |
WO2007143688A3 (en) | An apparatus and method for measuring of particles generated from medical devices or instruments utilized during simulated clinical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |